Modulators for SIRT6 and assays for screening same
Method for identifying a modulator of Sirt6, PfSir2a, or Sirt7 deacylase activity, wherein a fatty-acylated substrate containing an acyl-lysine moiety and an indicator moiety is contacted with Sirt6, PfSir2a, or Sirt7 in the presence of a candidate compound under conditions for Sirt6, PfSir2a, or Sirt7 to deacylate the substrate, wherein the acyl is a hydrophobic fatty acyl group containing a hydrocarbon group having at least three carbon atoms connected by carbon-carbon bonds; contacting the deacylated substrate with a cleavage agent that cleaves the linkage between the lysine and indicator moiety to generate a detectable signal; and correlating a quantified Sirt6, PfSir2a, or Sirt7 deacylase activity therefrom. Modulating compounds of Sirt6, PfSir2a, or Sirt7 deacylase activity are also described, as are pharmaceutical compositions thereof, methods of treatment by administration of the modulating compounds, and kits for practicing the method.
1. A compound that modulates Sirt6, PfSir2a, or Sirt7 deacylase activity, having the following chemical structure:
wherein R 1 is a hydrocarbon group having at least five carbon atoms connected by carbon-carbon bonds, wherein said hydrocarbon group optionally includes one heteroatom selected from O, N, and S that interrupts a carbon-carbon bond of said hydrocarbon group or replaces a carbon atom of said hydrocarbon group, except that said heteroatom is not included as an OH, SH, or NH 2 group, and wherein one or more hydrogen atoms in said hydrocarbon group is optionally replaced with fluoro atoms;
R 2 is selected from S, NR 6 , and 0 , wherein R 6 is a hydrogen atom or a hydrocarbon group R;
X 1 , X 2 , and X 3 are each —(CH 2 ) n —, wherein n independently represents 1, 2, or 3;
R 5 is a hydrogen atom or a hydrocarbon group R;
R 3 and R 4 are independently hydrogen atom or a hydrocarbon group R;
wherein said hydrocarbon groups R are independently either unsubstituted or substituted with one or more heteroatoms selected from N, O, S, P, and F or heteroatom groups containing one or more of said heteroatoms, wherein R 4 can alternatively be OH or SH.
2. The compound of claim 1 , wherein said hydrocarbon group for R 1 has at least five carbon atoms connected by carbon-carbon bonds in the absence of heteroatom substitution, except that one or more hydrogen atoms are optionally replaced with fluoro atoms.
3. The compound of claim 1 , wherein said hydrocarbon group for R 1 has at least six carbon atoms connected by carbon-carbon bonds wherein said hydrocarbon group optionally includes one heteroatom selected from O, N, and S that interrupts a carbon-carbon bond of said hydrocarbon group or replaces a carbon atom of said hydrocarbon group, except that said heteroatom is not included as an OH, SH, or NH 2 group, and wherein one or more hydrogen atoms in said hydrocarbon group is optionally replaced with fluoro atoms.
4. The compound of claim 1 , wherein said hydrocarbon group for R 1 has at least seven carbon atoms connected by carbon-carbon bonds wherein said hydrocarbon group optionally includes one heteroatom selected from O, N, and S that interrupts a carbon-carbon bond of said hydrocarbon group or replaces a carbon atom of said hydrocarbon group, except that said heteroatom is not included as an OH, SH, or NH 2 group, and wherein one or more hydrogen atoms in said hydrocarbon group is optionally replaced with fluoro atoms.
5. The compound of claim 1 , wherein said hydrocarbon group for R 1 has at least eight carbon atoms connected by carbon-carbon bonds wherein said hydrocarbon group optionally includes one heteroatom selected from O, N, and S that interrupts a carbon-carbon bond of said hydrocarbon group or replaces a carbon atom of said hydrocarbon group, except that said heteroatom is not included as an OH, SH, or NH 2 group, and wherein one or more hydrogen atoms in said hydrocarbon group is optionally replaced with fluoro atoms.
6. The compound of claim 1 , wherein said hydrocarbon group for R 1 has up to twenty carbon atoms.
7. The compound of claim 1 , wherein R 2 is S.
8. The compound of claim 1 , wherein R 3 and R 4 are each comprised of at least one amino acid residue.
9. A compound that functions as an acylated substrate in an assay for Sirt6, PfSir2a, or Sirt7 deacylase activity, having the following chemical structure:
wherein R 7 is a hydrocarbon group having at least five carbon atoms connected by carbon-carbon bonds, wherein said hydrocarbon group optionally includes one heteroatom selected from O, N, and S that interrupts a carbon-carbon bond of said hydrocarbon group or replaces a carbon atom of said hydrocarbon group, except that said heteroatom is not included as an OH, SH, or NH 2 group, and wherein one or more hydrogen atoms in said hydrocarbon group is optionally replaced with fluoro atoms;
R 8 is selected from S, NR 13 , and O, wherein R 13 is a hydrogen atom or a hydrocarbon group R;
X4, X5, and X6 are each —(CH2)n-, wherein n independently represents 1, 2, or 3;
R 11 is a hydrogen atom or a hydrocarbon group R;
R 9 and R 10 are independently hydrogen atom or a hydrocarbon group R, wherein R 10 can alternatively be OH or SH, and wherein at least one of R 9 and R 10 is an indicator moiety;
wherein said hydrocarbon groups R are independently either unsubstituted or substituted with one or more heteroatoms selected from N, O, S, P, and F or heteroatom groups containing one or more of said heteroatoms.
10. The compound of claim 9 , wherein said indicator moiety is a fluorophore.
11. The compound of claim 10 , wherein said fluorophore has an aminocoumarin structure.
12. The compound of claim 9 , wherein said hydrocarbon group for R 7 has at least five carbon atoms connected by carbon-carbon bonds in the absence of heteroatom substitution, except that one or more hydrogen atoms are optionally replaced with fluoro atoms.
13. The compound of claim 9 , wherein said hydrocarbon group for R 7 has at least six carbon atoms connected by carbon-carbon bonds wherein said hydrocarbon group optionally includes one heteroatom selected from O, N, and S that interrupts a carbon-carbon bond of said hydrocarbon group or replaces a carbon atom of said hydrocarbon group, except that said heteroatom is not included as an OH, SH, or NH 2 group, and wherein one or more hydrogen atoms in said hydrocarbon group is optionally replaced with fluoro atoms.
14. The compound of claim 9 , wherein said hydrocarbon group for R 7 has at least seven carbon atoms connected by carbon-carbon bonds wherein said hydrocarbon group optionally includes one heteroatom selected from O, N, and S that interrupts a carbon-carbon bond of said hydrocarbon group or replaces a carbon atom of said hydrocarbon group, except that said heteroatom is not included as an OH, SH, or NH 2 group, and wherein one or more hydrogen atoms in said hydrocarbon group is optionally replaced with fluoro atoms.
15. The compound of claim 9 , wherein said hydrocarbon group for R 7 has at least eight carbon atoms connected by carbon-carbon bonds wherein said hydrocarbon group optionally includes one heteroatom selected from O, N, and S that interrupts a carbon-carbon bond of said hydrocarbon group or replaces a carbon atom of said hydrocarbon group, except that said heteroatom is not included as an OH, SH, or NH 2 group, and wherein one or more hydrogen atoms in said hydrocarbon group is optionally replaced with fluoro atoms.
16. The compound of claim 9 , wherein said hydrocarbon group for R 7 has up to twenty carbon atoms.
17. The compound of claim 9 , wherein R 8 is S.
18. The compound of claim 9 , wherein one of R 9 and R 10 is comprised of at least one amino acid residue, and one of R 9 and R 10 is an indicator moiety.
19. The compound of claim 9 , wherein said indicator moiety is a fluorophore.
20. The compound of claim 19 , wherein said fluorophore has an aminocoumarin structure.
21. A method for treating a subject afflicted with a disorder characterized by an abnormal or non-optimal Sirt6 or Sirt7 deacylase activity, comprising administering to said subject a compound of claim 1 in a pharmaceutically effective amount for treating said disorder.